目的探討哈樂預防腹部手術后尿潴留的臨床價值。
方法哈樂組于拔尿管前1 d開始用哈樂0.2 mg,1次/d,3~5 d; 對照組未予特殊藥物治療。比較2組的尿潴留發生率、尿路感染發生率、住院時間和副作用。
結果哈樂組未發生尿潴留,對照組尿潴留發生率為28%,差異有統計學意義(P<0.05)。哈樂組無一例發生尿路感染,對照組有5例(20%),2組間差異無統計學意義(P gt;0.05)。哈樂組術后平均住院時間為(10.7±3.3) d,對照組為(11.6±3.0) d,2組間差異亦無統計學意義(P gt;0.05)。
結論哈樂可明顯減少尿潴留的發生率,是預防腹部手術后尿潴留的有效藥物。
引用本文:
張明鳴,伍曉汀,蔣漢卿,莊文,楊綱. 哈樂在預防腹部手術后尿潴留的應用. 中國普外基礎與臨床雜志, 2006, 13(3): 331-332. doi:
復制
1. |
Expert Opin Pharmacother, 2004; 5(1)∶151.
|
2. |
Lee E, Lee C. Clinical comparison of selective and nonselective alpha 1Aadrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses [J]. Br J Urol, 1997; 80(4)∶606.
|
3. |
Patel R, Fiske J, Lepor H. Tamsulosin reduces the incidence of acute urinary retention following early removal of the urinary catheter after radical retropubic prostatectomy [J]. Urology, 2003; 62(2)∶287.
|
4. |
楊竹, 鐘鈴, 胡麗娜. 坦索羅辛在婦科手術后尿潴留中的作用 [J]. 臨床泌尿外科雜志, 2002; 17(3)∶119.
|
5. |
Michel MC, de la Rosette JJ. Efficacy and safety of tamsulosin in the treatment of urological diseases [J].
|
- 1. Expert Opin Pharmacother, 2004; 5(1)∶151.
- 2. Lee E, Lee C. Clinical comparison of selective and nonselective alpha 1Aadrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses [J]. Br J Urol, 1997; 80(4)∶606.
- 3. Patel R, Fiske J, Lepor H. Tamsulosin reduces the incidence of acute urinary retention following early removal of the urinary catheter after radical retropubic prostatectomy [J]. Urology, 2003; 62(2)∶287.
- 4. 楊竹, 鐘鈴, 胡麗娜. 坦索羅辛在婦科手術后尿潴留中的作用 [J]. 臨床泌尿外科雜志, 2002; 17(3)∶119.
- 5. Michel MC, de la Rosette JJ. Efficacy and safety of tamsulosin in the treatment of urological diseases [J].